Dimerix (ASX: DXB) Discussion Thread, page-516

Not much of a poster here in recent years, but have been in DXB since 2016.

The inconclusive result in DKD the Phase 2 trial in 2020 was a disappointment (more a frustration since it might well have been the result of DMX-200 providing unexpected residual benefit post dosing). Dimerix took this in its stride - DKD on the backburner and full steam ahead with FSGS.

Now we are at another inflection point: if the current trial results are positive and the FDA approves Phase 3, we could see a step change in Dimerix - not only running the FSGS trial, but also having the resources to revisit DKD and maybe even start pre-clinical work on DMX-700. DKD itself is a huge potential market.